Derivation of totipotent-like stem cells with blastocyst-like structure forming potential.

Cell Res

MOE Engineering Research Center of Regenerative Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center and the MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Ce

Published: June 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

It is challenging to derive totipotent stem cells in vitro that functionally and molecularly resemble cells from totipotent embryos. Here, we report that a chemical cocktail enables the derivation of totipotent-like stem cells, designated as totipotent potential stem (TPS) cells, from 2-cell mouse embryos and extended pluripotent stem cells, and that these TPS cells can be stably maintained long term in vitro. TPS cells shared features with 2-cell mouse embryos in terms of totipotency markers, transcriptome, chromatin accessibility and DNA methylation patterns. In vivo chimera formation assays show that these cells have embryonic and extraembryonic developmental potentials at the single-cell level. Moreover, TPS cells can be induced into blastocyst-like structures resembling preimplantation mouse blastocysts. Mechanistically, inhibition of HDAC1/2 and DOT1L activity and activation of RARγ signaling are important for inducing and maintaining totipotent features of TPS cells. Our study opens up a new path toward fully capturing totipotent stem cells in vitro.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160264PMC
http://dx.doi.org/10.1038/s41422-022-00668-0DOI Listing

Publication Analysis

Top Keywords

stem cells
20
tps cells
20
cells
12
derivation totipotent-like
8
totipotent-like stem
8
totipotent stem
8
cells vitro
8
2-cell mouse
8
mouse embryos
8
stem
6

Similar Publications

Immunomodulatory Roles of Tonsil-Derived Mesenchymal Stem Cells.

Crit Rev Immunol

January 2025

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.

Stemming from human immune organs, tonsil-derived mesenchymal stem cells (TMSCs) hold unique strengths in differentiation potential and immune regulatory functions. These characteristics make them valuable for therapeutic applications, particularly in regenerative medicine and autoimmune disease treatment, as they can modulate immune responses and promote tissue repair. Their ability to interact with various cell types and secrete a range of bioactive molecules further enhances their role in orchestrating healing processes, making them a promising avenue for innovative therapies aimed at restoring balance in the immune system and facilitating recovery from injury or disease.

View Article and Find Full Text PDF

Nanomedicine-Mediated Therapies to Target Cancer Stem Cells: An Emerging Technology.

Crit Rev Ther Drug Carrier Syst

January 2025

Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.

Cancer stem cells (CSCs) are a category of cancer cells endowed with the ability to renew themselves, undergo unregulated growth, and exhibit a differentiation capacity akin to that of normal stem cells. CSCs have been linked with tumor metastasis and cancer recurrence due to their ability to elude immune monitoring. As a result, targeting CSCs specifically may improve the efficacy of cancer therapy.

View Article and Find Full Text PDF

The role of inflammation in the regulation of acute myeloid leukemia (AML) and stressed hematopoiesis is significant, though the molecular mechanisms are not fully understood. Here, we found that mesenchymal stromal cells (MSCs) had dysregulated expression of the inflammatory cytokine S100A8 in AML. Upregulating S100A8 in MSCs increased the proliferation of AML cells in vitro.

View Article and Find Full Text PDF

Purpose: To evaluate visual outcomes after bacterial keratitis (BK) and identify predictive factors for poor prognosis at a tertiary referral center in Southern California.

Methods: This is a cross-sectional retrospective review of patients' medical records with culture-positive BK at University of California Los Angeles from January 1, 2014, to December 31, 2019. Main outcome measure was change in best-corrected visual acuity (BCVA) at 12 weeks posttreatment.

View Article and Find Full Text PDF

Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by hyperactivation of the mechanistic/mammalian target of rapamycin 1 (mTORC1) growth pathway in a subset of mesenchymal lung cells. Histopathologically, LAM lesions have been described as immature smooth muscle-like cells positive for the immature melanocytic marker HMB45/PMEL/gp100 and phosphorylated ribosomal protein S6 (pS6). Advances in single cell sequencing (scRNA-seq) technology allowed us to group LAM cells according to their expression of cancer stem cell (CSC) genes and identify three clusters: a high CSC-like state (SLS), an intermediate state, and a low CSC-like inflammatory state (IS).

View Article and Find Full Text PDF